Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Adherium Ltd. ( (AU:ADR) ) is now available.
Adherium reported a strong December 2025 quarter, capping what it described as a transformational year marked by new leadership, resource restructuring and a sharper commercial focus. The company exceeded its calendar 2025 targets of 4,000 total Hailie Smartinhaler shipments and 2,000 RPM device shipments, shipped 1,384 units in the quarter (up 234% quarter-on-quarter), and recorded 752 new patient activations alongside a 233% lift in recurring RPM revenue between July and December. Customer receipts climbed to $479,000, up 257% on the prior quarter, driven by an AstraZeneca milestone payment and rising RPM subscriptions, while the November launch of the Hailie Care app has delivered more than 75% three-month patient retention, above typical adherence benchmarks. Management highlighted that its scaled RPM infrastructure, including a call centre with more than 40,000 insurance-verified asthma patients and improved US Medicare reimbursement settings from January 2026, positions the business for continued recurring revenue growth and progress toward its goal of 10,000 active RPM patients by end-2026.
The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.
More about Adherium Ltd.
Adherium Limited is an Australia-based medtech company specialising in digital respiratory management through its US FDA-cleared Hailie Smartinhaler platform. The company focuses on remote patient monitoring (RPM) and adherence solutions for asthma and other respiratory patients, targeting US and global healthcare markets, including value-based care insurers and clinics seeking technology-enabled chronic disease management.
Technical Sentiment Signal: Sell
Current Market Cap: A$17M
Learn more about ADR stock on TipRanks’ Stock Analysis page.